Abstract
Although the first two investigational anti-diabetic drugs to be assessed for increased cardiovascular risk by the US FDA are unlikely to require additional clinical trials before approval, companies are actively adapting their preclinical and clinical development programmes in response to last year's FDA guidance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Opar, A. Diabetes drugs pass cardiovascular risk check. Nat Rev Drug Discov 8, 343–344 (2009). https://doi.org/10.1038/nrd2890
Issue Date:
DOI: https://doi.org/10.1038/nrd2890
